Recruiting

MyMammogram DA

Sponsor:

Dartmouth-Hitchcock Medical Center

Code:

NCT06522568

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 39 - 49

Healthy Volunteers: Not accepted

Interventions

MyMammogram

Provider communication

Study Details

Brief summary:

The overall objective of this COBRE pilot project is to enhance the design of a 3-arm cluster randomized trial that will test the efficacy and mechanism of effect of the MyMammogram DA with or without a provider communication intervention. This will be accomplished through two aims: (1) Refine, with community partner input, a clinical trial protocol to optimize engagement among patients and primary care providers (PCPs) practicing in rural settings. In consultation with patients, PCPs, and informatics experts, the study team will refine site selection, randomization, patient and PCP recruitment, and data collection protocols to meet the needs of the rural health care delivery system and participants. The result of this aim will be a modified protocol and intervention strategy that is acceptable to partners. (2) Adapt and test trial and intervention implementation features to achieve protocol acceptance and adherence. The investigators will pilot the adapted three-arm randomized trial protocol in rural primary care settings that compares the MyMammogram DA with or without a risk summary provided to the PCP pre-visit, relative to usual care. Implementing the trial in two phases (n=15 each) will systematically identify barriers and facilitators to trial participation to refine protocols. Participants will receive acceptability surveys and investigators will conduct qualitative interviews with patients and PCPs to understand experiences with trial implementation from multiple perspectives.

Conditions

Breast Cancer

Study ID

NCT06522568

Start date

Sep 1, 2025

Status verified date

Aug, 2026

Completion date

Dec 15, 2026

Anticipated

Primary completion date

Nov 15, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 39 - 49

Healthy Volunteers: Not accepted

Patient Inclusion Criteria:

  • Females
  • Aged 39-49
  • Upcoming appointment with a participating primary care provider (within 4 weeks)
  • English or Spanish-speaking

Patient Exclusion Criteria:

  • Personal history of breast cancer (including lobular carcinoma in situ and ductal carcinoma in situ or atypical hyperplasia)
  • Mammogram in the prior 12 months

Clinician inclusion: Any practicing primary care provider at a participating site.

Study Design

Enrollment

39 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

no intervention: Usual Care

Usual care.

experimental: MyMammogram

Patient uses MyMammogram prior to appointment.

experimental: MyMammogram plus provider communication

Patient uses MyMammogram prior to appointment. Provider receives a summary from MyMammogram prior to appointment.

Interventions

MyMammogram

An online breast cancer screening decision aid

Provider communication

Provider will be provided with information from MyMammogram that includes patient's breast cancer risk and preferences for mammograms prior to the appointment

Primary outcome measure

  • Intervention acceptability [ Time Frame: within one day of completing the intervention ]

Central Contacts and Locations

Central contacts

Locations

Cheshire Medical Center

Recruiting

Keene, New Hampshire, United States, 03431

Contacts

New London Hospital Primary Care

Recruiting

New London, New Hampshire, United States, 03257

Contacts

Newport Health Center

Recruiting

Newport, New Hampshire, United States, 03773

Contacts

More Information

Sponsor

Dartmouth-Hitchcock Medical Center

Last update posted

Aug 31, 2026

Last verified

Aug, 2026

Keywords

  • Screening

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Dartmouth-Hitchcock Medical Center on 2026-08-31.